Malvern’s Aclaris Therapeutics is seeing positive results in mid-stage testing of its experimental treatment for common warts, a condition that currently does not have an FDA-approved medicine, writes John George for the Philadelphia Business Journal.

Aclaris saw its new drug candidate meet all the primary and secondary endpoints in two phase-II clinical trials of more than 300 patients.

“We are extremely pleased by these results,” said Dr. Neal Walker, a dermatologist and president and CEO of Aclaris. “This is an important milestone for the company’s wart program, and this data further substantiates the potential clinical utility of our proprietary formulation of A-101 45 percent topical solution.”

[uam_ad id=”58459″]

Advertisement

Based on the results of clinical tests, Aclaris is planning to meet with the FDA mid-year to determine the phase-III structure of the clinical trial program for its new drug candidate.

“We expect to initiate our phase-III program in the second half of 2018,” he said.

The third stage of clinical trials is usually the last hurdle that needs to be cleared successfully before FDA approval is sought for an experimental medicine.

Read more about the potential treatment in the Philadelphia Business Journal here, and check out previous VISTA Today coverage of Aclaris Therapeutics here.

[uam_ad id=”58462″]